Last reviewed · How we verify
NCT04618393
A Study of EMB-02 in Participants With Advanced Solid Tumors
Phase 1, PHASE2 trial testing EMB-02 in Advanced Solid Tumors in 47 participants. Terminated before completion.
12 July 2023
Quick facts
| Lead sponsor | Shanghai EpimAb Biotherapeutics Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 47 |
| Start date | 11 March 2021 |
| Primary completion | 12 July 2023 |
| Estimated completion | 21 March 2024 |
| Sites | 10 locations across China, United States, Australia |
Drugs / interventions tested
- EMB-02 — full drug profile →
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of EMB-02 will also be assessed.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L, Li Y, Tan J, Xu L, et al · · 2023 · cited 232× · PMID 37670328 · DOI 10.1186/s13045-023-01499-1 -
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0 -
Understanding LAG-3 Signaling.
Chocarro L, Blanco E, Zuazo M, Arasanz H, et al · · 2021 · cited 154× · PMID 34067904 · DOI 10.3390/ijms22105282 -
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J, Yang Y, Wang G, Liu M. · · 2022 · cited 127× · PMID 36389699 · DOI 10.3389/fimmu.2022.1035276 -
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application.
Huo JL, Wang YT, Fu WJ, Lu N, et al · · 2022 · cited 124× · PMID 35958563 · DOI 10.3389/fimmu.2022.956090 -
Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB, Ha SJ, Kim HR. · · 2021 · cited 81× · PMID 34025438 · DOI 10.3389/fphar.2021.681320 -
Clinical landscape of LAG-3-targeted therapy.
Chocarro L, Blanco E, Arasanz H, Fernández-Rubio L, et al · · 2022 · cited 69× · PMID 35755891 · DOI 10.1016/j.iotech.2022.100079 -
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
Surowka M, Schaefer W, Klein C. · · 2021 · cited 64× · PMID 34491877 · DOI 10.1080/19420862.2021.1967714
Verify or expand the search:
- PubMed search for NCT04618393
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Shanghai EpimAb Biotherapeutics Co., Ltd. trials
Trials by the same sponsor.
- NCT07432022 — A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in P · Phase 1, PHASE2 · not yet recruiting
- NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
- NCT05263180 — A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. · Phase 1 · unknown
- NCT05176665 — EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers · Phase 1, PHASE2 · recruiting
- NCT04735575 — A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04618393 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai EpimAb Biotherapeutics Co., Ltd.
- Last refreshed: 21 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04618393.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing